CD274 and neoplasm: Therefore, the basic principle of immune checkpoint inhibition is to use antibodies against PD-1, PD-L1, or CTLA-4 for treatment to reverse the inhibitory effect of immune checkpoints and promote anti-tumor effects by preventing the interaction of these receptors.